Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study

Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, et al. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol. 2019;37:1228–63.

Article  PubMed  Google Scholar 

Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8:1–7.

Article  Google Scholar 

van de Velde HJK, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399–406.

Article  PubMed  Google Scholar 

Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, et al. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Cancer Netw. 2022;20:8–19.

Article  Google Scholar 

Rosiñol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernández MT, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134:1337–45.

Article  PubMed  PubMed Central  Google Scholar 

Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, et al. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020;136:2513–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781–94.

Article  CAS  PubMed  Google Scholar 

Holstein SA, Hillengass J, McCarthy PL. Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase. J Clin Oncol. 2018;36:2101–4.

Article  CAS  PubMed  Google Scholar 

Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rychak E, Mendy D, Shi T, Ning Y, Leisten J, Lu L, et al. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br J Haematol. 2016;172:889–901.

Article  CAS  PubMed  Google Scholar 

Ocio EM, Fernández-Lázaro D, San-Segundo L, López-Corral L, Corchete LA, Gutiérrez NC, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia. 2015;29:705–14.

Article  CAS  PubMed  Google Scholar 

International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma [Internet]. Int. Myeloma Found. 2022. https://www.myeloma.org/resource-library/international-myeloma-working-group-imwg-uniform-response-criteria-multiple.

Lahuerta JJ, Paiva B, Vidriales MB, Cordón L, Cedena MT, Puig N, et al. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol. 2017;35:2900–10.

Article  CAS  PubMed  Google Scholar 

Kumar S, Jacobus SJ, Cohen AD, Weiss M, Callander NS, Singh AA, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRD) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial. J Clin Oncol. 2020;38:LBA3.

Article  Google Scholar 

Radhakrishnan VS, Tamboli N, Das S, Garg JK, Nag A, Bhave SJ, et al. Bortezomib-Pomalidomide-Dexamethasone (VPD) As Novel Induction Therapy in Newly-Diagnosed Multiple Myeloma: Early Safety Data from an Ongoing Single Arm Phase-II Investigator-Initiated Clinical Trial (PRIME Study). Blood. 2021;138:2752.

Article  Google Scholar 

Zamagni E, Nanni C, Gay F, Dozza L, Rota Scalabrini D, Omedé P, et al. MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial. Blood. 2019;134:4321.

Article  Google Scholar 

Cedena MT, Martin-Clavero E, Wong S, Shah N, Bahri N, Alonso R, et al. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. PloS ONE. 2020;15:e0237155.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zamagni E, Nanni C, Gay F, Dozza L, Rota Scalabrini D, D’Agostino M, et al. Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial. Blood. 2020;136:27–8.

Article  Google Scholar 

Culakova E, Thota R, Poniewierski MS, Kuderer NM, Wogu AF, Dale DC, et al. Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med. 2014;3:434–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106:3777–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pancheri E, Guglielmi V, Wilczynski GM, Malatesta M, Tonin P, Tomelleri G, et al. Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects. Cancers. 2020;12:2540.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Plummer C, Driessen C, Szabo Z, Mateos MV. Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J. 2019;9:1–12.

Article  CAS  Google Scholar 

Yanamandra U, Malhotra P. Stem Cell Transplantation in Multiple Myeloma: Very Much Alive and Kicking. Indian J Hematol Blood Transfus. 2019;35:205–7.

Article  PubMed  PubMed Central  Google Scholar 

Cowan AJ, Baldomero H, Atsuta Y, Mikhael J, Aljurf M, Seber A, et al. The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study. Biol Blood Marrow Transplant. 2020;26:2372–7.

Article  PubMed  PubMed Central  Google Scholar 

Kulkarni U, Devasia AJ, Korula A, Fouzia N, Nisham P, Samoon YJ, et al. Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant. Biol Blood Marrow Transplant. 2018;24:e31–5.

Article  PubMed  Google Scholar 

Braunlin M, Belani R, Buchanan J, Wheeling T, Kim C. Trends in the multiple myeloma treatment landscape and survival: a US analysis using 2011–2019 oncology clinic electronic health record data. Leuk Lymphoma. 2021;62:377–86.

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif